Progress in the biological understanding and management of breast cancer-associated central nervous system metastases

Oncologist

Volumn 18, Issue 6, 2013, Pages 675-684

  Dawood, Shaheenah ^b   Gonzalez Angulo, Ana M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DUBAI HOSPITAL   (United Arab Emirates)

Author keywords

Biology; Breast cancer; CNS metastases; Leptomeningeal disease; Treatment

Indexed keywords

BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; CAPECITABINE; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EFAPROXIRAL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GLUCOSE TRANSPORTER 1; LAPATINIB; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PHENYTOIN; PREDNISONE; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VALPROIC ACID; VELIPARIB; VINCRISTINE;

ARTICLE; AUTOPSY; BLOOD BRAIN BARRIER; BRAIN DYSFUNCTION; BRAIN EDEMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CENTRAL NERVOUS SYSTEM METASTASIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; GLIOBLASTOMA; HUMAN; MENINGEAL CYST; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SERIAL ANALYSIS OF GENE EXPRESSION; SOLID TUMOR; STEREOTACTIC RADIOSURGERY;

BIOLOGY; BREAST CANCER; CNS METASTASES; LEPTOMENINGEAL DISEASE; TREATMENT;

BLOOD-BRAIN BARRIER; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; MENINGEAL NEOPLASMS; PROGNOSIS; RADIOSURGERY; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84879465394     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0438     Document Type: Article

References (95)

1. Patel RR, Mehta MP. Targeted therapyfor brain metastases: Improving the therapeutic ratio. Clin Cancer Res 2007;13:1675-1683.
2. Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol 2006;24:1289-1294.
3. Chang JE, Robins HI, Mehta MP. Therapeuticad-vances in the treatment of brain metastases. Clin Adv Hematol Oncol 2007;5:54-64.
4. Gaspar L, Scott C, Murray K et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for the brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001-1006.
5. Lin NU, Bellon JR, Winer EP. CNSmetastases in breast cancer. J Clin Oncol 2004;22:3608-3617.
6. Miller KD, Weathers T, Haney LG et al. Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. Ann Oncol 2003;14:1072-1077.
7. Tsukada Y, Fouad A, Pickren JW et al. Central nervoussystem metastasisfrom breast carcinoma. Autopsystudy. Cancer1983;52:2349-2354.
8. Stark AM, Stohring C, Hedderich J et al. Surgical treatment for brain metastases: Prognostic factors and survival in 309 patients with regard to patient age. J Clin Neurosci 2011;18:34-38.
9. Gonzalez-Angulo AM, Cristofanilli M, Strom EA et al. Central nervoussystem metastases in patients withhigh-riskbreastcarcinomaaftermultimodality treatment. Cancer 2004;101:1760-1766.
10. Dawood S, Broglio K, Esteva FJ et al. Survival of women with triple-receptor negative breast cancer and brain metastases. Ann Oncol 2009;20:621-627.
11. Patanaphan V, Salazar OM, Risco R. Breastcancer: Metastatic pattern and their prognosis. South Med J 1988;81:1109-1112.
12. Harputluoglu H, Dizdar O, Aksoy S et al. Characteristics of breast cancer patients with central nervoussystem metastases: Asingle-centerexperi-ence. J Natl Med Assoc 2008;100:521-526.
13. De Angelis L, Rogers L, Foley KM. Leptomenin-geal metastasis. In: Harris JR, ed. Diseases of the breast. Philadelphia, PA: Lippincott William & Wilkins, 2000:867-874.
14. Hawkins BT, Davis TP. The blood-brain barrier/ neurovascularunitin health and disease. Pharmacol Rev 2005;57:173-185.
15. Regina A, Demeule M, Laplante A et al. Multidrug resistance in brain tumors: Roles of the blood-brain barrier. Cancer Metastasis Rev 2001; 20:13-25.
16. Zhang RD, Price JE, Fujimaki Tet al. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992; 141:1115-1124.
17. Yonemori K, Tsuta K, Ono Met al. Disruptionof the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010; 116:302-308.
18. van Vulpen M, Kal HB, Taphoorn MJ et al. Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? Oncol Rep 2002;9:683-688.
19. Stemmler HJ, Schmitt M, Willems Aet al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18: 23-28.
20. Smith QR, Rudraraju V, Taskar Ket al. Lapatinib distribution in brain metastases of breast cancer following oral dosing in mice. Paper presented at: Breast Cancer Symposium, Abstract 158; Septem-ber5-7, 2008; Washington, D.C.
21. Lin NU, Dieras V, Paul D et al. Multicenter phase II studyoflapatinibin patients with brain me-tastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-1459.
22. Bachelot T, Romieu G, Campone M et al. Lapa-tinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A singlegroup phase 2 study. Lancet Oncol 2013;14:64-71.
23. Pitz MW, Desai A, Grossman SA et al. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neu-rooncol 2011;104:629-638.
24. Bos PD, Zhang XH, Nadal Cet al. Genesthatme-diate breastcancermetastasistothe brain. Nature 2009;459:1005-1009.
25. SØrlie T, Perou CM, Tibshirani Ret al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA2001;98:10869-10874.
26. Kennecke H, Yerushalmi R, Woods Ret al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-3277.
27. Berghoff A, Bago-Horvath Z, De Vries C et al. Brain metastases free survival differs between breast cancersubtypes. Br J Cancer 2012;106:440-446.
28. Musolino A, Ciccolallo L, Panebianco M et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: Epidemiological and clinical data from a population-based cancer registry study. Cancer 2011;117:1837-1846.
29. Bria E, Cuppone F, Fornier Met al. Cardiotoxic-ityand incidenceofbrain metastasesafteradjuvant trastuzumab for early breast cancer: The dark side ofthemoon?Ameta-analysisoftherandomizedtri-als. Breast Cancer Res Treat 2008;109:231-239.
30. Lin NU, Claus E, Sohl J et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Can-cer2008;113:2638-2645.
31. Vern-Gross TZ, Lawrence JA, Case LD et al. Breast cancersubtype affects patterns offailure of brain metastases after treatment with stereotactic radiosurgery. J Neurooncol 2012;110:381-388.
32. Sperduto PW, Kased N, Roberge D et al. Effect oftumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012;82:2111-2117.
33. Ryken TC, McDermott M, Robinson PD et al. Theroleofsteroidsinthe managementofbrain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96: 103-114.
34. Yung W, Kunschner L, Saway R et al. Intracranial metastases. In: Levin V, ed. Cancer in the ner vous system. 2nd ed. New York, NY: Oxford University Press, 2002:321-340.
35. Mikkelsen T, Paleologos NA, Robinson PDet al. Theroleofprophylacticanticonvulsantsin theman-agement of brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:97-102.
36. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_ gls/pdf/cns.pdf. Accessed November1,2013.
37. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment ofsingle metastases to the brain. N Engl J Med 1990;322: 494-500.
38. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 2004;363: 1665-1672.
39. Kondziolka D, Patel A, Lunsford LD et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999;45:427-434.
40. Patchell RA, Tibbs PA, Regine WFet al. Postoperative radiotherapy in the treatment ofsingle me-tastases to the brain: A randomized trial. JAMA 1998;280:1485-1489.
41. Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006;295:2483-2491.
42. Roos DE, Wirth A, Burmeister BH et al. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Ra-diother Oncol 2006;80:318-322.
43. Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irra-diation:Arandomised controlledtrial. Lancet Oncol 2009;10:1037-1044.
44. Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-141.
45. Scoccianti S, Ricardi U. Treatmentofbrain me-tastases: Reviewofphase III randomized controlled trials. Radiother Oncol 2012;102:168-179.
46. Davey P, Hoegler D, Ennis M et al. A phase III study of accelerated versus conventional hypofrac-tionated whole brain irradiation in patients of good performance status with brain metastases not suitable forsurgical excision. Radiother Oncol 2008;88: 173-176.
47. Graham PH, Bucci J, Browne L. Randomized comparison of whole brain radiotherapy, 20 Gy in four daily fractions versus 40 Gy in 20 twice-daily fractions, for brain metastases. Int J Radiat Oncol Biol Phys 2010;77:648-654.
48. Suh JH, Stea B, Nabid A et al. Phase III study of Efaproxiral as an adjunct to whole brain radiation therapy for brain metastases. J Clin Oncol 2006;24: 106-114.
49. Antonadou D, Coliarakis N, Paraskevaidis M et al. Whole brain radiotherapy alone or in combination with temozolomide for brain metastases. A phase III trial. Int JRadiat Oncol Biol Phys2002;54:93-94.
50. Guerrieri M, Wong K, Ryan G et al. A randomized phase III study of palliative radiation with concomitant carboplatin for brain metastases from nonsmall cell carcinoma of the lung. Lung Cancer 2004;46:107-111.
51. Neuhaus T, Ko Y, Muller RPet al. Aphase III trial oftopotecan and whole brain radiation therapyfor patients with CNS metastases due to lung cancer. Br J Cancer 2009;100:291-297.
52. Knisely JPS, Berkey B, Chakravarti A et al. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy formultiple brain metastases (RTOG 0118). Int JRadiat Oncol Biol Phys 2008;71:79-86.
53. Chargari C, Kirova YM, Dieras V et al. Concur-rentcapecitabineandwhole-brain radiotherapyfor treatment of brain metastases in breast cancer patients. J Neurooncol 2009;93:379-384.
54. Serizawa T, Iuchi T, Ono J et al. Gamma knife treatment for multiple metastatic brain tumors compared with whole-brain radiation therapy. J Neurosurg 2000;93(suppl 3):32-36.
55. Park SH, Hwang SK, Kang DH et al. Gamma knife radiosurgery for multiple brain metastases from lungcancer. J Clin Neurosci 2009;16:626-629.
56. Suzuki S, Omagari J, Nishio Set al. Gammaknife radiosurgery for simultaneous multiple metastatic brain tumors. J Neurosurg2000;93(suppl 3):30-31.
57. Amendola BE, Wolf A, Coy S et al. Radiosurgery as palliation forbrain metastases:Aretrospective review of 72 patients harboring multiple lesions at presentation. J Neurosurg 2002;97(suppl):511-514.
58. Nam TK, Lee JI, Jung YJ et al. Gamma knife sur-geryforbrain metastases in patientsharboringfour or more lesions: Survival and prognostic factors. J Neurosurg2005;102(suppl):147-150.
59. Bhatnagar AK, Flickinger JC, Kondziolka Det al. Stereotacticradiosurgeryforfourormore intracranial metastases. Int J Radiat Oncol Biol Phys 2006; 64:898-903.
60. Karlsson B, Hanssens P, Wolff Ret al. Thirtyyears' experience with Gamma Knife surgery for metastases to the brain. J Neurosurg 2009;111:449-457.
61. Knisely JP, Yamamoto M, Gross CP et al. Radiosurgery alone for 5 or more brain metastases: Expert opinion survey. J Neurosurg2010;113(suppl):84-89.
62. Chargari C, Idrissi HR, Pierga JYet al. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int J Radiat Oncol Biol Phys2011;81:631-636.
63. Lin NU, Ramakrishna N, Younger WJ et al. Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breastcancer. J Clin Oncol 2010;28(suppl):1154.
64. Xu Z, Marko NF, Chao STet al. Relationship between HER2 status and prognosis in women with brain metastases from breast cancer. Int J Radiat Oncol Biol Phys2012;82:e739-e747.
65. O'Meara WP, Seidman AD, Yamada Yet al. Impact of HER2 status in breast cancer patients receiving stereotactic radiosurgery for brain metastases. J Clin Oncol 2005;23(suppl):637.
66. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58:832-839.
67. Boogerd W, Vos VW, Hart AAet al. Brain metastases in breastcancer; natural history, prognosticfac-tors and outcome. J Neurooncol 1993;15:165-174.
68. Ekenel M, Hormigo AM, Peak S et al. Capecit-abine therapy ofcentral nervous system metastases from breastcancer. J Neurooncol 2007;85:223-227.
69. Boogerd W, Groenveld F, Linn S et al. Chemotherapy as primary treatment for brain metastases from breast cancer: Analysis of 115 one-year survivors. J Cancer Res Clin Oncol 2012;138:1395-1403.
70. Lim E, Lin NU. Newinsightsand emergingther-apies for breast cancer brain metastases. Oncology (Williston Park) 2012;26:652-659,663.
71. Lassman AB, Abrey LE, Shah GD et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006;78:255-260.
72. Siena S, Crino L, Danova M et al. Dose-dense temozolomide regimen for the treatment of brain me-tastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: A multicenter phase II study. Ann Oncol 2010;21:655-661.
73. Christodoulou C, Bafaloukos D, Linardou H et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patientswith brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (He COG) Phase II study. J Neurooncol 2005;71:61-65.
74. Murphy C, Nulsen B, Rump Met al. Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring afterwhole brain radiotherapy(WBXRT). Paperpre-sented at ASCO Breast Cancer Symposium; 2009; Abstract no. 234.
75. Freedman RA, Bullitt E, Sun L et al. A phase II studyofsagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer2011;11:376-383.
76. Dawood S, Broglio K, Esteva FJ et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008;19: 1242-1248.
77. Le Scodan R, Jouanneau L, Massard C et al. Brain metastases from breast cancer: Prognostic signifi-canceof HER-2overexpression, effectoftrastuzumab andcauseofdeath. BMCCancer2011;11:395.
78. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-1999.
79. Boccardo F, Kaufman B, Baselga J et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2 + breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). J Clin Oncol 2008;26(suppl):1094.
80. Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastasesthe UK experience. Br J Cancer 2010;102:995-1002.
81. Metro G, Foglietta J, Russillo M et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011;22:625-630.
82. Lin NU, Eierman W, Greil R et al. Randomized phase II studyoflapatinib pluscapecitabineorlapa-tinibplustopotecan forpatientswith HER2-positive breastcancerbrain metastases. J Neurooncol 2011; 105:613-620.
83. Ro J, Park S, Kim S et al. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: An open-label expanded access study in Korea. BMCCancer2012;12:322.
84. Thomas FC, Taskar K, Rudraraju Vet al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 2009;26:2486-2494.
85. Sarantopoulos J, Gabrail NY, Moulder SL et al. ANG1005: Resultsofa Phase I study in patients with advanced solid tumorsandbrain metastases. Paper presented at: 2010 ASCO Annual Meeting; June 4-8 2011; Chicago, IL.
86. Lin NU, Schwartzberg LS, Kesari S et al. A phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer. Paper presented at San Antonio Breast Cancer Symposium, San Anto-nio, TX, Poster3-12-04; December4-8, 2012.
87. Niwinska A, Tacikowska M, Murawska M. The effectofearlydetection ofoccult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys 2010;77:1134-1139.
88. Huang F, Alrefae M, Langleben Aet al. Prophylactic cranial irradiation in advanced breast cancer: Acaseforcaution. Int JRadiat Oncol Biol Phys 2009; 73:752-758.
89. Pivot X, Zurawski B, Allerton R et al. Cerebel (EGF111438): An open label randomized phase III studycomparing the incidence of CNS metastases in patients with HER2+ metastatic breast cancer, treatedwithlapatinibpluscapecitabineversustras-tuzumab plus capecitabine. Ann Oncol 2012; 23(suppl 9):ixe1-ixe30.
90. Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol 2010;22:627-635.
91. Lassman AB, Abrey LE, Shah GD et al. Systemic high-dose intravenous methotrexate for central nervoussystem metastases. J Neurooncol 2006;78: 255-260.
92. Platini C, Long J, Walter S. Meningeal carcino-matosisfrombreastcancertreatedwith intrathecal trastuzumab. Lancet Oncol 2006;7:778-780.
93. Mir O, Ropert S, Alexandre Jet al. High-dose intrathecal trastuzumab for leptomeningeal metas-tases secondary to HER-2 overexpressing breast cancer. Ann Oncol 2008;19:1978-1980.
94. Mego M, Sycova-Mila Z, Obertova J et al. Intrathecal administration of trastuzumab with cytara-bine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast 2011; 20:478-480.
95. Oliveira M, Braga S, Passos-Coelho JL et al. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 2011; 127:841-844.